19:04:19 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-07-23 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning MNTC 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-03 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-20 Kvartalsrapport 2023-Q2
2023-05-12 Ordinarie utdelning MNTC 0.00 SEK
2023-05-11 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-03 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-28 Ordinarie utdelning MNTC 0.00 SEK
2022-04-27 Årsstämma 2022
2022-02-03 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning MNTC 0.00 SEK
2021-05-06 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-04 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning MNTC 0.00 SEK
2020-05-27 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-08-28 Extra Bolagsstämma 2019

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Mentice är verksamt inom medicinteknik. Bolaget utvecklar medicinska instrument för endovaskulär simulering samt för träningstillfällen inom kirurgi. Programmen är utvecklade för att användas i utbildningssyfte bland sjukhus och institut. Störst verksamhet återfinns inom Nordamerika och Europa. Utöver huvudverksamheten erbjuds möjligheter till leasing, support, samt teknisk service. Huvudkontoret ligger i Göteborg.
2023-05-09 10:00:00

The newly established Mentice Spain S.L. office in the heart of Barcelona, Spain, will serve as an additional hub for Mentice group’s software development, with an initial focus on the recently acquired, CE-marked Ankyras® intracranial aneurysm decision support solution.

The new regional office will focus on advancing simulation-based decision-support solutions in clinical practice as part of Mentice’s strategy to expand its business vertically within the Image-Guided Interventional Therapies (IGIT) market.

Mentice AB (STO: MNTC) today announced the opening of a new regional office in Barcelona, Spain. Setting up the new company is part of the integration work following last year’s acquisition of Ankyras® - a solution that provides simulated assessment for the planning of neurovascular flow diversion in the treatment of intracranial aneurysms. The new company, Mentice Spain S.L., will focus on research, development, and the manufacturing of medical software products.

With the introduction of increasingly complex procedures and devices, such as flow diverters, in the interventional market over the last few years, the demand for solutions that support device manufacturers with optimal design and physicians in making informed treatment choices has increased. Also, the rapid growth of image analysis and AI technology in medical imaging has opened the door to new approaches for effectively addressing this need. Barcelona has proven to be a strategic location for innovation and a wealth of software development resources, complementing Mentice R&D Head Quarter in Gothenburg, Sweden.

“The establishment of Mentice Spain S.L. is a huge step for Mentice on our journey to pivot from a simulation company to a provider of clinical performance solutions for procedural and device adoption,” said Edward Fält, VP of M&A and Strategy at Mentice. “We now have the technology and regulatory tools we need to develop medical imaging solutions and to integrate closely into the clinical workflow, with clear synergies for training and rollout of new interventional devices. Manufacturers and hospitals will now, for the first time, have access to a unique set of solutions covering both device design, training, and planning, all from a single vendor.”

In the mid-term, Mentice plans to further integrate the clinical-decision support application within the current solution portfolio, including virtual, physiological, and cloud simulation. This allows users to build personalized procedural and case data libraries to repurpose application scenarios.

To learn more about Ankyras - Braided Device Sizing Support Application, visit, mentice.com/ankyras

Mentice subsidiaries and partners will distribute the medical software products developed and manufactured by Mentice Spain S.L. in approved markets.